-transparent.png){kind=logo}
Twenty-four patients with advanced metastatic colorectal cancer with measurable sites of disease were treated with a combination of 5-FU, methyl-CCNU, ICRF-159, and triazinate. Only two had objective regression of disease. Two patients died of complications from drug-induced myelosuppression. Toxic effects were moderate in the remaining patients. Attempts to escalate doses were limited by myelosuppression. The regimen used has no advantage over 5-FU alone. It is unlikely that triazinate and ICRF-159 will add substantially to the efficacy of chemotherapy for colorectal cancer.
Related Publications
S E Vogl, and
R Qazi, and
M Berenzweig
January 1980,
Oncology,
S E Vogl, and
R Qazi, and
M Berenzweig
March 1978,
Cancer treatment reports,
S E Vogl, and
R Qazi, and
M Berenzweig
June 1979,
Tumori,
S E Vogl, and
R Qazi, and
M Berenzweig
January 1978,
Medical and pediatric oncology,
S E Vogl, and
R Qazi, and
M Berenzweig
November 1976,
Cancer treatment reports,
S E Vogl, and
R Qazi, and
M Berenzweig
January 1980,
Cancer treatment reports,
S E Vogl, and
R Qazi, and
M Berenzweig
January 1981,
Cancer treatment reports,
S E Vogl, and
R Qazi, and
M Berenzweig
January 1981,
Medical and pediatric oncology,
S E Vogl, and
R Qazi, and
M Berenzweig
April 1986,
Cancer treatment reports,
S E Vogl, and
R Qazi, and
M Berenzweig
February 1986,
American journal of clinical oncology,
